Relapsed high-grade serous ovarian cancer (HGSOC) is the main cause of epithelial ovarian cancer (EOC)-related morbidity and mortality. EU-funded researchers are investigating factors contributing to recurrent EOC to find novel solutions.
EOC patients initially respond well to first-line surgery and chemotherapy, but most relapse and acquire platinum resistance resulting in their death. The OCTIPS (Ovarian cancer therapy – Innovative models prolong survival) project is studying the molecular mechanisms involved in the development of recurrent EOC to improve therapeutic efficacy.
Further details: Elucidating recurrent ovarian cancer